---
id: idsa-c-diff-2024
title: "IDSA/SHEA 2024 Clinical Practice Guideline Update: Clostridioides difficile Infection in Adults"
short_title: "IDSA C. diff 2024"

organization: Infectious Diseases Society of America
collaborators:
  - Society for Healthcare Epidemiology of America
country: US
url: https://www.idsociety.org/guidelines/
doi: null
pmid: null
open_access: true

specialty: infectious-disease
guideline_type: clinical-practice
evidence_system: IDSA GRADE
conditions:
  - Clostridioides difficile
  - C. difficile colitis
  - CDI
tags:
  - vancomycin
  - fidaxomicin
  - bezlotoxumab
  - fecal microbiota transplant
  - recurrent CDI

publication_date: 2024-07-01
previous_version_date: 2021-01-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-24
---

## Scope
2024 IDSA/SHEA guideline update on the diagnosis and treatment of Clostridioides difficile infection (CDI) in adult patients.

## Key Recommendations

### Diagnosis
- **Stool Testing**: Use a multistep algorithm (GDH/toxin EIA + NAAT) or NAAT alone for symptomatic patients only.
- Do NOT test asymptomatic patients or test of cure.

### Initial Episode (Non-Fulminant)
- **First-Line**: Fidaxomicin 200 mg PO BID x 10 days (preferred due to lower recurrence).
- **Alternative**: Vancomycin 125 mg PO QID x 10 days.
- **Avoid Metronidazole**: Use only if vancomycin/fidaxomicin are unavailable.

### Fulminant CDI
- Vancomycin 500 mg PO/NG QID + Metronidazole 500 mg IV q8h.
- Consider vancomycin rectal enema if ileus.
- Surgical consultation for toxic megacolon, perforation, or refractory shock.

### Recurrent CDI

#### First Recurrence
- Fidaxomicin (preferred) or vancomycin tapered/pulsed regimen.

#### Second or Further Recurrence
- Fidaxomicin extended-pulsed regimen OR
- Fecal Microbiota Transplantation (FMT) or FDA-approved microbiota-based products (e.g., Vowst, Rebyota) are recommended for patients with â‰¥2 recurrences.

### Bezlotoxumab
- Anti-toxin B monoclonal antibody. Consider for patients at high risk for recurrence (age >65, immunocompromised, severe initial episode, prior CDI, concomitant antibiotics).

### Infection Prevention
- Antibiotic stewardship.
- Contact precautions and hand hygiene (soap and water preferred over alcohol-based sanitizers).
